STRATEC Annual General Meeting: Shareholders elect new Supervisory Board and approve dividend increase

Birkenfeld, June 18, 2014

At today's Annual General Meeting in Pforzheim, the shareholders of STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) approved all of the agenda items put to the vote with large majorities in each case.

Prof. Dr. Stefanie Remmele, Landshut, Professor for medical engineering at the Hochschule Landshut - University of Applied Sciences, was newly elected to the three-member Supervisory Board and thus succeeds Prof. Dr. Hugo Hämmerle. The previous Supervisory Board Chairman, Fred K. Brückner, and the previous Deputy Supervisory Board Chairman, Wolfgang Wehmeyer, stood for re-election and were once again elected to the supervisory body by the Annual General Meeting.
At the subsequent constitutive meeting of the Supervisory Board, Fred K. Brückner was once again elected as Chairman. Wolfgang Wehmeyer was re-elected as Deputy Supervisory Board Chairman and as the independent financial expert pursuant to § 100 (5) of the German Stock Corporation Act (AktG).

STRATEC is distributing a dividend of EUR 0.60 per share to its shareholders for the 2013 financial year (previous year: EUR 0.56). The distribution total amounts to EUR 7.1 million and will be paid to shareholders via their depository banks from June 20, 2014. The dividend has thus been increased for the tenth year in succession since the initiation of dividend payments in 2004.

Further information about the Annual General Meeting can be found on the company's website at www.stratec.com/agm.

About STRATEC
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies.
Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.

Further information can be obtained from:
STRATEC Biomedical AG
André Loy, Corporate Communications
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
ir@stratec.com
www.stratec.com